Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$55.80 USD

55.80
2,334,423

-0.01 (-0.02%)

Updated May 13, 2024 04:00 PM ET

After-Market: $55.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inogen's (INGN) Preliminary Q4 Revenues Solid Amid Challenges

by Zacks Equity Research

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.

Quidel Corporation (QDEL) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Quidel's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued robust sales of its SARS-related products.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Catalent (CTLT) owing to its robust facility expansion activities and a slew of strategic deals.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Catalent (CTLT) Down 6.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Why Catalent (CTLT) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Catalent (CTLT) Q1 Earnings Top Estimates, FY22 View Up

by Zacks Equity Research

Catalent's (CTLT) robust performance across most of its segments drives its first-quarter fiscal 2022 top line.

Catalent (CTLT) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 7.58% and 1.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Catalent (CTLT) Expands Presence in Japan Via New Facility

by Zacks Equity Research

Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings

Debanjana Dey headshot

MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

by Debanjana Dey

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

Why Is Catalent (CTLT) Up 2.1% Since Last Earnings Report?

by Zacks Equity Research

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Catalent (CTLT) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Moderna (MRNA) Inks Vaccine Manufacturing Deal With Resilience

by Zacks Equity Research

Moderna (MRNA) is expanding its manufacturing and fill-finish capacities through collaborations deals with multiple companies to support the supply of its COVID-19 vaccine.

Catalent's (CTLT) Q4 Earnings Top Estimates, Margins Rise

by Zacks Equity Research

Catalent's (CTLT) robust performance across the majority of its segments drives its fourth-quarter fiscal 2021 top line.

Catalent (CTLT) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 11.54% and 5.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q4 results.

Catalent (CTLT) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.